Table 3

Cardiovascular parameters of SHR treated for 3 months with candesartan-cilexetil (3 mg/kg/day), mibefradil (18 mg/kg/day), or a combination of both (0.9 and 9 mg/kg/day, respectively)

ControlCandesartanMibefradilCombination
Δ Systolic blood pressure (mm Hg) +14.9  ± 4.43-c −36.7  ± 4.73-a 3-c −36.7  ± 4.93-b 3-c −28.6  ± 3.63-a 3-c
Δ Heart rate (bpm)13.1  ± 5.915.2  ± 7.16.9  ± 5.322.5  ± 7.9
Left ventricular weight (mg)1025  ± 10742  ± 123-a 990  ± 13833  ± 153-a 3-b
ACE-activity (pmol/h/mg of protein)27.2  ± 0.823.4  ± 0.83-a 28.2  ± 0.727.6  ± 0.6
ANG plasma concentration (pg/ml)65.5  ± 11.1335.0  ± 74.83-a 59.3  ± 16.5151.7  ± 28.63-a 3-b

Values are expressed as means ± S.E.M. (n = 14–15).

  • ↵3-a  p < 0.05 vs. controls.

  • ↵3-b  p < 0.05 vs. candesartan-cilexetil.

  • ↵3-c  p < 0.05 vs. before treatment.